UNSPSC 51111632: Diflomotecan

This classification denotes a camptothecin analogue with the molecular formula C21H16F2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QKT1LC4J1P, chemically known as 3h,15h-oxepino(3,4:6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-, (5r)- but generally known as diflomotecan, which bears US NIH Compound Identifier 219023. The term DIFLOMOTECAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46).

Most nations schedule diflomotecan under HS 29399900 and SITC 54149. As of Q4 2014, DIFLOMOTECAN remains the US FDA Preferred Term for this commodity. Diflomotecan bears US NLM identifiers UMLS ID C1541796 and NCI Concept Code C90824. SMILES: CC[C@]1(CC(=O)OCC2=C1C=C3C4=C(CN3C2=O)C=C5C=C(C(=CC5=N4)F)F)O.

UNSPSC 51111632 Diflomotecan is a Commodity code naming a specific topoisomerase-1 inhibitor pharmaceutical used in oncology, but the source contains no recent state or local contract opportunities for this product.

State and local procurement activity under this code cannot be characterized based on available information. Without documented solicitations, issuing-body patterns, geographic concentration, or representative opportunities, no decision signal is available to business development professionals evaluating pursuit under this code at present.